Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H32O2 |
Molecular Weight | 304.4669 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])CC(=O)[C@H](C)C[C@]34C
InChI
InChIKey=IKXILDNPCZPPRV-RFMGOVQKSA-N
InChI=1S/C20H32O2/c1-12-11-20(3)13(10-17(12)21)4-5-14-15-6-7-18(22)19(15,2)9-8-16(14)20/h12-16,18,22H,4-11H2,1-3H3/t12-,13+,14+,15+,16+,18+,19+,20+/m1/s1
DescriptionSources: http://steroid.es/drostanolone.html
Sources: http://steroid.es/drostanolone.html
Dromostanolone Propionate (known by the brand names Masteron and Drolban) was invented by Syntex in 1959. About 10 years later it was released on the American market by Lilly as brand name Drolban. The drug was first approved in the USA for use as a treatment of female breast cancer. However, the profile of side-effects included pronouncement of male characteristics in women and when more effective breast cancer treatments came to market drostanolone was gradually phased out. No longer used clinically dromostanolone propionate became very popular in the bodybuilding community. Today dromostanolone propionate remains on the list of approved medications, but it is not being manufactured or sold by pharmaceutical companies. It is still produced illegally by underground labs for use in the bodybuilding community.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3758193 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Drolban Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 4 times / day multiple, oral Dose: 100 mg, 4 times / day Route: oral Route: multiple Dose: 100 mg, 4 times / day Sources: |
unhealthy, adult n = 9 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 9 Sources: |
Disc. AE: Hypertriglyceridemia... AEs leading to discontinuation/dose reduction: Hypertriglyceridemia (5 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypertriglyceridemia | 5 patients Disc. AE |
100 mg 4 times / day multiple, oral Dose: 100 mg, 4 times / day Route: oral Route: multiple Dose: 100 mg, 4 times / day Sources: |
unhealthy, adult n = 9 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 9 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: http://steroid.es/drostanolone.html
Unknown
Route of Administration:
Intramuscular
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C243
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-Drostanolone
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
||
|
DEA NO. |
4000
Created by
admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Drostanolone
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
PRIMARY | |||
|
m4767
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
PRIMARY | Merck Index | ||
|
C1076
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
PRIMARY | |||
|
7DR7H00HDT
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
PRIMARY | |||
|
DTXSID6022971
Created by
admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
|
PRIMARY | |||
|
3319
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
PRIMARY | |||
|
23678
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
PRIMARY | RxNorm | ||
|
6011
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
PRIMARY | |||
|
C100263
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
PRIMARY | |||
|
DB00858
Created by
admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
|
PRIMARY | |||
|
SUB06414MIG
Created by
admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
|
PRIMARY | |||
|
1159
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
PRIMARY | |||
|
100000081008
Created by
admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
|
PRIMARY | |||
|
34838
Created by
admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
|
PRIMARY | |||
|
58-19-5
Created by
admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201048
Created by
admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
|
PRIMARY | |||
|
200-367-9
Created by
admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY